Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Novartis AG

35 indications, side-by-side phase, drug & LoA

$151.56

-1.51 (-0.99%)

A 85Pipeline Score Fair Value Pharma · Commercial
Market Cap
277.73 B
EPS
7.06
P/E Ratio
21.66 $
Value Trade
220.72 M
1.26 %
Week
2.31 %
1 Month
-6.55 %
3 Month
20.76 %
6 Month
82.32 %
5 Year
866.4 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
1.68 M
52 Week Range
111.06 - 170.46
% held by Insiders
0.01 %
% held by Institutions
7.94 %
Enterprise Value
318.17 B
Total Shares
1.83 B
Short %
0.25 %
Float Shares
1.83 B
Company Description
Employees:75,267
https://www.novartis.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A85
Pipeline Score
$167.3B
Pipeline Value
Fair Value
Valuation Signal
674
Drugs Scored
2.0x
rNPV / MCap
Top 98%
Large Pharma
(rank 19 of 905)
Percentile Rank
Novartis AG earns an A-grade pipeline score (85/100), with $167.4B risk-adjusted pipeline value, led by zoledronic acid in Metastatic Cancer (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Zoledronic acid
Small molecule		Treatment of Bone MetastasesPhase 3NCT0021925858% $23.6B COMPLETED 240 - -— -Nov 23, 2009
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in NVS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Novartis AG (NVS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
NVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
NVS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
NVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-12-180 0.00 0 0 - - - - - -
2026-12-180 0.00 0 0 - - - - - -
2026-12-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How NVS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Valvular Heart Disease #1 of 13 PHASE 2 Pelacarsen
KNSA ABT ·dev EW ·dev
 $14.89B 0.84 LEADER
Sarcoma #1 of 30 PHASE 3 cisplatin + doxorubicin + etoposide + ifosfamide + methotrexate + zoledronic acid
INTS LLY PFE
$1.75B 0.78 LEADER
Dyslipidemia / Hypercholesterolemia #1 of 14 PHASE 3 inclisiran
ARWR MRK AZN
—0.88 LEADER
Thrombocytopenia #1 of 18 PHASE 3 Ianalumab + Corticosteroids
TAK ARGX AMGN
$1.85B 0.88 LEADER
IgA Nephropathy #1 of 8 PHASE 3 BION-1301
VERA TVTX BIIB
$46.82B 0.89 LEADER
Lupus Nephritis #1 of 17 PHASE 3 ianalumab s.c. q4w + ianalumab s.c. q12w
VTRS AZN AUTL
$1.2B 0.75 LEADER
Urticaria #1 of 11 PHASE 3 LOU064
CLDX PFE EVMN
$2.5B 0.9 LEADER
Glomerular Diseases #1 of 6 PHASE 3 zigakibart
APLS VRTX VERA
—0.89 LEADER
Sjogren's Syndrome #1 of 10 PHASE 3 VAY736
AMGN BMY JNJ
$0.3B 0.9 LEADER
Huntington's Disease #1 of 5 PHASE 3 Votoplam
NBIX ALNY QURE
$0.77B 0.9 LEADER
Autoimmune Hemolytic Anemia #1 of 8 PHASE 3 Ianalumab
ZBIO RIGL JNJ
$0.77B 0.82 LEADER
Asthma #2 of 16 PHASE 3 QVM149 + Salmeterol Xinafoate / Fluticasone Propionate + Run-In Medication
TEVA GSK SNY
$30.84B 0.94 LEADER
Rare Hematological Disorders #2 of 17 PHASE 3 Iptacopan
AZN VRTX REGN
—0.9 CONTENDER
Atherosclerosis #2 of 15 PHASE 3 Inclisiran in
NVO LLY AMGN
$35.43B 0.92 LEADER
Thyroid Cancer #2 of 12 PHASE 3 Dabrafenib + Trametinib
LLY EXEL MRK
$4.2B 0.86 CONTENDER
Sickle Cell Disease #2 of 12 PHASE 3 Crizanlizumab
NVO SNY VRTX
$4.23B 0.9 CONTENDER
Spinal Muscular Atrophy #2 of 7 PHASE 3 Onasemnogene Abeparvovec-xioi
BIIB BHVN SRRK
$2.5B 0.93 CONTENDER
Dengue #2 of 5 PHASE 2 EYU688
TAK SNY ABT ·dev
 $2.26B 0.85 CONTENDER
Membranous Nephropathy #2 of 7 PHASE 3 LNP023
BIIB ONC VRTX
$0.39B 0.89 CONTENDER
Malaria #2 of 3 PHASE 2 INE963 + KAE609 + KLU156
GSK SXTP
$1.13B 0.85 CONTENDER
Rare Genetic Disorders #3 of 61 PHASE 3 everolimus
BMRN ASND SNY
—0.87 LEADER
Atrial Fibrillation #3 of 16 PHASE 2 PKN605
REGN JNJ MIST
$27.0B 0.88 CONTENDER
Coronary Artery Disease #3 of 20 PHASE 3 Inclisiran
NVO BSX ·dev ALNY
$4.72B 0.94 LEADER
Multiple Sclerosis #3 of 20 PHASE 3 Remibrutinib + Teriflunomide
SNY BMY BIIB
$31.92B 0.9 LEADER
Myeloproliferative Neoplasms #3 of 14 PHASE 3 Pelabresib + Ruxolitinib
BMY ABBV KPTI
—0.88 CONTENDER
Hidradenitis Suppurativa #3 of 13 PHASE 3 secukinumab
ABBV INCY MLTX
$1.7B 0.89 LEADER
Mesothelioma #3 of 15 PHASE 1 IAG933
AZN MRK BMY
$0.65B 0.74 CONTENDER
Dyslipidemia #3 of 9 PHASE 3 TQJ230
LLY MRK NAMS
$16.03B 0.93 CONTENDER
Diabetic Nephropathy #3 of 4 PHASE 2 Atrasentan
DXCM ·dev REGN PROK
$3.51B 0.91 CONTENDER
Skin Cancer #3 of 4 PHASE 2 Dabrafenib + Trametinib
REPL MDWD REGN
$18.7B 0 CONTENDER
Focal Segmental Glomerulosclerosis #3 of 6 PHASE 2 Atrasentan
APLS SNY AKBA
$3.31B 0.91 CONTENDER
Systemic Lupus Erythematosus #4 of 32 PHASE 3 Ianalumab
BIIB BMY VTRS
$2.78B 0.82 LEADER
Myasthenia Gravis #4 of 19 PHASE 3 Remibrutinib
ARGX AZN JNJ
$2.18B 0.79 CONTENDER
Systemic Sclerosis #4 of 21 PHASE 2 rapcabtagene autoleucel + rituximab
AZN BMY MRK
$2.68B 0.78 CONTENDER
ALS #4 of 15 PHASE 2 VHB937
AMLX BIIB IONS
$0.14B 0.8 CONTENDER
Rare Immunological Disorders #4 of 10 PHASE 3 zigakibart
AMGN ZBIO PHVS
—0.9 CONTENDER
Other Solid Tumors #4 of 5 PHASE 1 KFA115 + pembrolizumab
MRK INCY IOVA
$2.5B 0.76 CONTENDER
Chronic Kidney Disease #5 of 27 PHASE 3 zigakibart
AZN LLY NVO
$96.33B 0.95 CONTENDER
Hypertension #5 of 16 PHASE 2 QCZ484
LLY ALNY MLYS
$9.41B 0.96 CONTENDER
Vasculitis #5 of 16 PHASE 2 Iptacopan + Rituximab
AZN GSK ABBV
$15.2B 0.81 CONTENDER
Vitiligo #5 of 8 PHASE 2 GIA632
INCY PFE ABBV
$1.31B 0.91 CONTENDER
Breast Cancer #6 of 94 PHASE 3 Ribociclib
AZN MRK LLY
$10.85B 0.84 CONTENDER
Lymphoma #6 of 69 PHASE 3 Tisagenlecleucel + Lenalidomide and rituximab in 28-day cycles for up to 12 cycles. + Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone in 21-day cycles for 6 to 8 cycles + Lymphodepleting chemotherapy
REGN LLY AZN
$8.52B 0.84 CONTENDER
Rheumatoid Arthritis #6 of 28 PHASE 2 VAY736 PFS + VAY736 AI
ABBV LLY BMY
$4.2B 0.9 FOLLOWER
Myelodysplastic Syndromes #6 of 33 PHASE 2 decitabine + spartalizumab + sabatolimab + azacitidine + venetoclax + INQOVI
BMY ABBV TAK
$2.5B 0.88 FOLLOWER
Leukemia #7 of 64 PHASE 3 Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib
AMGN MRK LLY
$4.28B 0.88 CONTENDER
Prostate Cancer #7 of 53 PHASE 3 177Lu-PSMA-617 + 68Ga-PSMA-11 + ARDT + ADT
MRK AZN PFE
$25.12B 0.8 CONTENDER
Alzheimer's Disease #7 of 24 PHASE 2 VHB937
BMY LLY BIIB
$6.49B 0.85 FOLLOWER
Age-Related Macular Degeneration #7 of 13 PHASE 2 Iptacopan
ABBV OCUL FDMT
$15.43B 0.91 CONTENDER
Bacterial Infections #8 of 31 PHASE 2 Cryptosporidium parvum oocysts + EDI048
PFE SNY GSK
$10.5B 0.98 FOLLOWER
Brain Tumors #9 of 44 PHASE 2 Dabrafenib + Trametinib
NVCR JAZZ DAWN
$3.55B 0.74 FOLLOWER
Heart Failure #9 of 30 PHASE 1 HJB647 low dose
NVO AZN CYTK
$22.0B 0.91 FOLLOWER
Psoriatic Arthritis #9 of 12 PHASE 1 Secukinumab
ABBV JNJ BMY
—0.95 FOLLOWER
Schizophrenia #9 of 15 PHASE 2 GXV813
NBIX BMY ALKS
$3.5B 0.95 FOLLOWER
Atopic Dermatitis #10 of 25 PHASE 2 GIA632
LLY ABBV PFE
$20.76B 0.84 FOLLOWER
Melanoma #12 of 52 PHASE 2 LXH254 + LTT462 + Trametinib + Ribociclib
MRK BMY REGN
$10.5B 0.85 CONTENDER
Esophageal Cancer #13 of 39 PHASE 1 KFA115 + pembrolizumab
AZN MRK ONC
$1.85B 0.76 FOLLOWER
Non-Small Cell Lung Cancer #14 of 88 PHASE 3 JDQ443 + docetaxel
MRK AZN RVMD
$28.1B 0.75 CONTENDER
Colorectal Cancer #16 of 82 PHASE 2 Dabrafenib + Trametinib
ABBV BMY MRK
$7.68B 0.72 CONTENDER
Ovarian Cancer #16 of 60 PHASE 2 Dabrafenib + Trametinib
MRK AZN LLY
$4.11B 0.71 FOLLOWER
Rare Metabolic Disorders #16 of 30 PHASE 1 DFT383
AZN SNY TVTX
$21.15B 0.9 FOLLOWER
Kidney Cancer #17 of 38 PHASE 1 KFA115 + pembrolizumab
BMY MRK AZN
$7.31B 0.76 FOLLOWER
Lung Cancer #23 of 78 PHASE 2 JDQ443
MRK GILD AMGN
$28.1B 0.76 CONTENDER
Multiple Myeloma #23 of 27 PHASE 2 Dabrafenib + Trametinib
BMY ABBV TAK
$23.78B 0 FOLLOWER
Endometrial Cancer #23 of 46 PHASE 1 Tulmimetostat + Enzalutamide
MRK AZN GILD
$31.09B 0.66 FOLLOWER
Head and Neck Cancer #24 of 62 PHASE 1 DKY709 + PDR001
AZN GSK JNJ
$10.2B 0.8 FOLLOWER
Pancreatic Cancer #32 of 72 PHASE 1 Ga-NNS309 + Lu-NNS309
RVMD RCUS AZN
$3.7B 0.57 FOLLOWER
Rare Neurological Disorders #33 of 46 PHASE 1 EDK060, dose A
IONS BIIB SRPT
$139.4B 0.9 FOLLOWER